Larimar Therapeutics Inc.

12/16/2024 | Press release | Distributed by Public on 12/16/2024 06:14

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.